Osteoporosis involves a condition, which occurs when the rate of regeneration of bone is much lower than its rupture, making the bones porous. Osteoporosis is more prevalent in women, where more cases occur after menopause due to decreased levels of estrogen hormone. In osteoporosis, the strength and structure of bones are affected, which increases the likelihood of fractures, especially in the hip region, wrists and spine. An X-ray scanning method, dual energy X-ray absorptiometry (DEXA) or bone densitometry is used to diagnose the condition. Osteoporosis has no obvious symptoms, although it is characterized by weakened spine and joint pain.
Request a sample copy of this research report: www.coherentmarketinsights.com/insight/request-sample/2525
Driver of the anti-osteoporosis and fracture healing market
In the recent past, various regulatory agencies such as the European Medicines Agency (EMA), the US Food and Drug Administration (FDA), the Medicines and Health Products Regulatory Agency (MHRA) and others have approved new drugs for the treatment of osteoporosis. The approval and launch of these new drugs is expected to lead to global growth in the anti-osteoporosis market and fracture during the forecast period. For example, in April 2017, Radius Health Inc., a biopharmaceutical company, received approval from the US Food and Drug Administration (FDA) for the injection of TYMLOS (abaloparatide), for the treatment of postmenopausal women with osteoporosis at high risk of fracture. This drug reduces the onset of spinal cord and peripheral skeleton fractures in postmenopausal women.
Restrictions on the market of anti-osteoporosis healing and fracture
The bisphosphonate pills, a drug commonly used for osteoporosis, are not well absorbed in the stomach and are involved with side effects such as stomach pain and heartburn. Furthermore, a greater awareness of osteoporosis, especially in women, led to the consumption of a diet rich in calcium and vitamins and adaptation of physiotherapy measures to prevent the occurrence of osteoporosis. These factors should curb the global growth of the anti-osteoporosis market and the fracture during the forecast period.
Key players in the anti-osteoporosis and fracture therapy market
Some of the main players operating in the osteoporosis and fracture care market are Radius Health Inc., Pfizer Inc., Amgen Inc., Novartis AG, GlaxoSmithKline Plc., Merck & Co., Inc., F. Hoffman – La Roche AG, Eli, Lilly and Company Limited and PhytoHealth Corporation.
Regional analysis of the anti-osteoporosis and fracture market
The anti-osteoporosis and fracture repair market in North America is expected to register significant growth in the forecast period due to the launch of new products. For example, in September 2018, Zydus Pharma Inc. received approval from the US Food and Drug Administration (FDA) for the release of delayed-release tablets of Risedronate Sodium in America, a drug used for the treatment of osteoporosis in postmenopausal women.
Download the brochure in PDF: www.coherentmarketinsights.com/insight/request-pdf/2525
About Coherent Market Insights:
Coherent Market Insights is an important market research and consultancy company that offers unified research reports, customized market analysis, consulting services and competitive analysis through various recommendations related to emerging market trends. to technologies and potential opportunities in dollars.
Insights on the coherent market
1001 4th Ave,
Seattle, WA 98154
Tel: + 1-206-701-6702
This version was published on openPR.